The safety of low-molecular weight heparins for the prevention of thromboembolic events after cardioversion of atrial fibrillation

Japanese Heart Journal

Volumn 44, Issue 3, 2003, Pages 369-377

  Y̌igit, Zerrin ^a,b   Küçüǩoglu, M Serdar ^a   Ökçün, Baris ^a   Sansoy, Vedat ^a   Güzelsoy, Deniz ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Atrial fibrillation; Cardioversion; Low molecular weight heparin; Transesophageal echocardiography

Indexed keywords

AMIODARONE; DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; QUINIDINE SULFATE; WARFARIN; FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HEART LEFT ATRIUM; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT OUTCOME; ECHOGRAPHY; FEASIBILITY STUDY; MIDDLE AGED;

AGED; ATRIAL FIBRILLATION; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; ELECTRIC COUNTERSHOCK; FEASIBILITY STUDIES; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; THROMBOEMBOLISM;

EID: 0037492584     PISSN: 00214868     EISSN: 1348673X     Source Type: Journal    
DOI: 10.1536/jhj.44.369     Document Type: Article

References (29)

1. Lip GHY. Paroxysmal atrial fibrillation. In : Lip G, editor. Atrial Fibrillation in Clinical Practice. First edition, London, Martin Dunitz Ltd, 2001: 137-47.
2. Laupacis A, Alberts G, Dunn M, Feinberg W. Antithrombotic therapy in atrial fibrillation. Chest 1992; 102: 426-31.
3. Klein AL, Grimm RA, Black IW, et al. Cardioversion guided by transesophageal echocardiography : the ACUTE Pilot Study - a randomized, controlled trial. Assessment of cardioversion using transesophageal echocardiography. Ann Intern Med 1997; 126: 200-9.
4. Klein AL, Grimm RA, Murray DOR, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344: 1411-20.
5. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
6. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
7. Weitz JI. Low-molecular weight heparins. N Engl J Med 1997; 337: 688-98.
8. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 1998; 114: 516S-578S.
9. Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol 1969; 23: 208-16.
10. Spinler SA, Nawarskass JJ. Low-molecular-weight heparins for acute coronary syndromes. Ann Pharmacother 1998; 32: 103-10.
11. Fatkin D, Kuchar DL, Thorburn CW, Feneley MP. Transesophageal echocardiography before and during current cardioversion of atrial fibrillation : evidence for "atrial stunning" as a mechanism of thromboembolic complications. J Am Coll Cardiol 1994; 23: 307-16.
12. Black IW, Fatkin D, Sagar KB, et al. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation: A multicenter study. Circulation 1994; 89: 2509-13.
13. Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 1992; 19: 581-5.
14. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis : a meta-analysis. BJM 1994; 309: 299-304.
15. Goldman MJ. The management of chronic atrial fibrillation : indications for and method of conversion to sinus rhythm. Prog Cardiovasc Dis 1960; 2: 465-79.
16. Aschenberg W, Schülter M, Kremer P, Schroder E, Siglow V, Bleifeld W. Transesophageal two-dimensional echocardiography for the detection of left atrial appendage thrombus. J Am Coll Cardiol 1986; 7: 163-6.
17. Pritchett ELC. Management of atrial fibrillation. N Engl J Med 1992; 326: 1264-71.
18. Mayet J, Wasan B, Sutton GC. Cardioversion of atrial arrhytmias : audit of anticoagulation management. J Royal Coll Phys London 1997; 31: 313-6.
19. Schlicht JR, Davis RC, Naqi K, Cooper W, Rao BV. Physician practices regarding anticoagulation and cardioversion of atrial fibrillation. Arch Intern Med 1996; 156: 290-4.
20. Manning WJ, Silverman DI, Gordon SPE, Krumholz HM, Douglas PS. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med 1993; 328: 750-5.
21. Manning WJ, Silverman DI, Keighley CS, Oettgen P, Douglas PS. Transesophageal echocardiography facilitated early cardioversion from atrial fibrillation using short-term anticoagulation : final results of a prospective 4.5 year study. J Am Coll Cardiol 1995; 25: 1354-61.
22. Stoddard MF, Dawkins PR, Prince CR, Longaker RA. Transesophageal echocardiographic guidence of cardioversion in patients with atrial fibrillation. Am Heart J 1995; 129: 1204-15.
23. Corrado G, Tadeo G, Berretta S, et al. Atrial thrombi resolution after prolonged anticoagulation in patients with atrial fibrillation. Chest 1999; 115: 140-3.
24. Yigit Z, Küçükoglu S, Sansoy V, et al. TEE-guided cardioversion is feasible and safe in patients with nonvalvular atrial fibrillation. Arch Turkish Soc Cardiol 1998; 26: 348-53.
25. Seto TB, Taira DA, Tsevat J, Manning WJ. Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with atrial fibrillation. J Am Coll Cardiol 1997; 29: 122-30.
26. Murray RD, Jasper SE, Goodman A, et al. Cost analysis model of low molecular weight heparin for antithrombotic therapy in patients undergoing TEE-guided cardioversion from atrial fibrillation (Abstract). J Am Coll Cardiol 1999; 33: 294A.
27. Noble S, Peters DH, Goa KL. Enoxaparin: a reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs 1995; 49: 388-410.
28. Roijer A, Eskilsson J, Olsson B. Transesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter : selection of a low-risk group for immediate cardioversion. Eur Heart J 2000; 21: 837-47.
29. Murray RD, Deitcher SR, Shah A, et al. Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation. J Am Soc Echocardiogr 2001; 14: 200-8.